货号:A455841
同义名:
福沙吡坦二甲葡胺
/ MK-0517; L785298
Fosaprepitant Dimeglumine是一种阿普瑞必妥的前药,阿普瑞必妥是一种选择性且高亲和力的NK1受体拮抗剂。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Known to induce vomiting, substance P binds to NK-1 receptors in the abdominal vagus, the NTS and the area postrema. Compounds that block NK-1 receptors lessen emesis after cisplatin, ipecac, apomorphine and radiation therapy[3]. Aprepitant is a selective NK-1 receptor antagonist approved as a therapy for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Fosaprepitant is a water-soluble phosphoryl prodrug for aprepitant, which, when administered intravenously, is converted to aprepitant within 30 min via the action of ubiquitous phosphatases[3]. Injection of the NK-1 receptor antagonists fosaprepitant directly into the vicinity of the NTS neurons inhibited cisplatin-induced emesis in the ferret, which suggested fosaprepitant may exert its main anti-emetic action centrally by depressing the neural activity of the NTS neurons, with possibly some peripheral anti-emetic effect through blockade of NK-1 receptors located on vagal terminals in the gut[3]. Preclinical toxicology studies of bolus fosaprepitant administered in seconds to dogs and rats showed that concentrations of 1 mg/ml were well tolerated. Concentrations up to 25 mg/ml at low doses (2 – 4 mg/kg/day) were well tolerated in dog[4]. |
| Concentration | Treated Time | Description | References | |
| SY5Y | 5 µM | 72 hours | Evaluate cell death and proliferation capacity, showing relative resistance | Oncotarget. 2017 Jan 3;8(1):430-443 |
| SK-N-AS | 0.85 µM | 72 hours | Determine IC50 values, showing a specific effect on malignant cells | Oncotarget. 2017 Jan 3;8(1):430-443 |
| IMR5 | 0–80 µM | 72 hours | Assess the effect of TACR1 inhibition on neuroblastoma cell viability, observed a concentration-dependent reduction in cell viability | Oncotarget. 2017 Jan 3;8(1):430-443 |
| Administration | Dosage | Frequency | Description | References | ||
| Wistar rats | Colorectal distension-induced vagal reflex model | Intraperitoneal injection | 30 mg/kg | Single dose, colorectal distension performed 40 minutes after administration | To investigate the effect of fosaprepitant on the circulatory response induced by colorectal distension. Results showed that fosaprepitant reduced the blood pressure drop caused by colorectal distension and decreased the number of c-Fos immunoreactive cells in the caudal ventrolateral medullary region. | Front Pharmacol. 2022 Oct 19;13:1020685 |
| Nude mice | IMR5 xenograft model | Intraperitoneal injection | 60 mg/kg body weight/day | Once daily for 14 days | Assess the effect of fosaprepitant on tumor burden, observed significant delay in tumor growth | Oncotarget. 2017 Jan 3;8(1):430-443 |
| New Zealand White rabbits | Joint contracture model | Intra-articular injection | 1 mL (1 mg) | Injected at 3, 6, 12, and 24 hours after surgery | To assess the effect of SP inhibition on pro-fibrotic gene expression in a post-traumatic joint contracture model. Results showed that fosaprepitant significantly altered the expression of pro-fibrotic genes but had no significant effect on joint contracture angles. | J Cell Biochem. 2018 Feb;119(2):1326-1336 |
| Dose | Rat: 1 mg/kg, 8 mg/kg[3] (i.v.) |
| Administration | i.v. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00090207 | Nausea Vomiti... 展开 >>ng 收起 << | Phase 4 | Completed | - | - |
| NCT00726960 | Opioid-Related Disorders ... 展开 >> Heroin Dependence Substance-Related Disorders 收起 << | Phase 1 | Unknown | June 2010 | Sweden ... 展开 >> Karolinska University Hospital, Huddinge Stockholm, Sweden, 14186 收起 << |
| NCT00717054 | Nausea Vomiti... 展开 >>ng 收起 << | Not Applicable | Completed | - | United States, Pennsylvania ... 展开 >> Hahnemann University Hospital Philadelphia, Pennsylvania, United States, 19102 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.00mL 0.20mL 0.10mL |
4.98mL 1.00mL 0.50mL |
9.95mL 1.99mL 1.00mL |
|
| CAS号 | 265121-04-8 |
| 分子式 | C37H56F7N6O16P |
| 分子量 | 1004.83 |
| SMILES Code | OC[C@H]([C@H]([C@@H]([C@H](CNC)O)O)O)O.OC[C@H]([C@H]([C@@H]([C@H](CNC)O)O)O)O.O=C1NC(CN2[C@H]([C@H](OCC2)O[C@H](C)C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C4=CC=C(C=C4)F)=NN1P(O)(O)=O |
| MDL No. | MFCD23102059 |
| 别名 | 福沙吡坦二甲葡胺 ;MK-0517; L785298; Fosaprepitant dimeglumine salt; Fosaprepitant(dimeglumine) |
| 运输 | 蓝冰 |
| InChI Key | VRQHBYGYXDWZDL-OOZCZQCLSA-N |
| Pubchem ID | 135564864 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
H2O: 50 mg/mL(49.76 mM),配合低频超声助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1